Journal article
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap
Abstract
The landscape of genetic testing in ovarian cancer patients has changed dramatically in recent years. The therapeutic benefits of poly ADP-ribose polymerase (PARP) inhibitors in treatment of BRCA1/2-related ovarian cancers has resulted in an increased demand and urgency for genetic testing results, while technological developments have led to widespread use of multi-gene cancer panels and development of tumour testing protocols. Traditional …
Authors
McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K
Journal
Journal of Medical Genetics, Vol. 55, No. 9,
Publisher
BMJ
Publication Date
September 2018
DOI
10.1136/jmedgenet-2018-105472
ISSN
0022-2593